AI illustration · not actual product photoDetails from the source.
This catalogue entry records PEG MGF, 2 mg × 10 vials (SKU FMP2), using the supplied source listing. The cited dossier describes: Research has examined endogenous MGF/IGF-1 isoform expression after muscle exercise or injury, and proposed roles in skeletal-muscle repair and regeneration. MGF-related peptides have also been studied in cultured cells and animal models involving muscle and cardiac injury. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- FMP2
- Source specification
- 2mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Catalogue-listed as PEG MGF, SKU FMP2; the supplied PDF specifies *10vials and 81 per 10 vials (currency unstated). Biologically, MGF refers to human IGF-1Ec, an IGF-1 splice variant; research also uses synthetic MGF E-domain fragments. The catalogue label does not verify that this vial is a specific sequence or PEG conjugate, so its exact molecular identity and whether it is a peptide preparation cannot be confirmed.
Biological mechanism
The endogenous IGF-1Ec transcript encodes a distinct C-terminal region of an IGF-1 precursor that can be processed into mature IGF-1 and E-domain material. A mechanism for free MGF E-domain peptides is unresolved; proposed actions that differ from canonical IGF-1 receptor signaling remain uncertain, and some claimed cell effects were not reproduced. No mechanism can be assigned to this exact vial without a defined identity.
Research focus
Research has examined endogenous MGF/IGF-1 isoform expression after muscle exercise or injury, and proposed roles in skeletal-muscle repair and regeneration. MGF-related peptides have also been studied in cultured cells and animal models involving muscle and cardiac injury. These lines of inquiry are experimental, not established clinical uses.
Potential applications in the evidence
Only investigational research questions can be described: muscle repair/regeneration and related responses to injury, plus MGF-fragment experiments in cardiac injury models. These are not established applications or evidence of benefit for the catalogue item. Findings about endogenous MGF, unmodified fragments, or other IGF-1 forms do not establish effects of PEG MGF.
Human evidence
A small study in ten healthy men measured endogenous MGF mRNA after exercise-induced muscle damage; it also tested a synthetic MGF E peptide in cultured cells. It did not administer PEG-MGF to people. A separate study found no claimed effects of native or stabilized MGF peptides on myoblast proliferation or differentiation in tested human and mouse cell models. FDA reports it has not identified human exposure data for drug products containing PEG-MGF by any route. Human therapeutic benefit and a human safety profile for this catalogue vial are not established.
Known and potential effects
The source literature describes changes in endogenous MGF gene expression after exercise or injury and mixed cell/animal findings for MGF-related fragments. Human adverse effects of PEG-MGF are not adequately characterized. FDA identifies potential immunogenicity risk for certain routes and concerns about peptide-related impurities and active-ingredient characterization in compounded PEG-MGF drugs. No specific adverse-effect profile is established for this vial.
Safety and contraindications
FDA states that compounded drugs containing PEG-MGF may pose significant immunogenicity risk for certain routes and may raise peptide impurity and active-ingredient characterization complexities; it lacks important safety information and has not identified human exposure data for PEG-MGF drug products. This does not establish that the catalogue product is compounded. With the vial identity and quality undocumented, risks and contraindications cannot be reliably specified. The evidence does not support describing it as safe.
U.S. FDA / regulatory status
No FDA-approved PEG-MGF medicine was established in the sources reviewed. FDA discusses potential risks of compounded PEG-MGF drugs but that is not an approval determination or proof that this exact vial is compounded. The catalogue gives no manufacturer, lot, formulation source, jurisdiction, or approval documentation; whether the exact vial is FDA-approved, compounded, or research-only cannot be verified. Do not imply that any status associated with an active ingredient or a different product transfers to this vial.
Evidence limitations
Evidence is limited, mixed, and mostly based on endogenous gene-expression observations, cell experiments, or animal research. These findings do not demonstrate benefit or safety of an externally supplied PEG-MGF product in humans. Research on non-PEG MGF fragments or full-length IGF-1 splice variants cannot be treated as evidence for a vial whose exact identity is undocumented.
Supporting sources
- Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks U.S. Food and Drug Administration · Regulatory safety communication. Supports: FDA's concerns about immunogenicity, peptide-related impurities/API characterization, lack of identified human exposure data, and limited safety knowledge for compounded PEG-MGF; does not establish the status of this catalogue vial.
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Frontiers in Endocrinology · Peer-reviewed opinion/review. Supports: IGF-1Ec splice-variant biology, proposed MGF-related mechanisms and experimental muscle/cardiac repair research, plus uncertainty around endogenous E-peptides and mechanism.
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells PubMed / American Journal of Physiology-Endocrinology and Metabolism · Peer-reviewed primary study. Supports: Primary cell experiments reporting no apparent effects of tested native/stabilized MGF peptides on myoblast proliferation/differentiation, challenging earlier claims.
- Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide Actions In Vitro In Vivo · Peer-reviewed primary human observational and in-vitro study. Supports: Study of ten men reporting transient endogenous MGF mRNA up-regulation after exercise-induced muscle damage and in-vitro testing; it did not administer PEG-MGF to humans.
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review Acta Biochimica et Biophysica Sinica / PubMed Central · Peer-reviewed review. Supports: Scientific background on IGF-1Ec/MGF splice variant identity and mixed findings across experimental literature.